Clinical research to estimate the predictive capacity of SEEDCHRONY on the success of the cryotransfer with a single euploid blastocyst: Seedchrony03
Uterine readiness for embryo transfer in IVF patients undergoing euploid blastocyst transfer
An intrauterine measurement of a biomarker dissolved in endometrial fluid will be conducted on the day of embryo transfer using the investigational device Seedchrony (RUO). This device incorporates a microsensor within a guiding catheter to quantify biomarker levels in uterine fluid entering the catheter. The measurement procedure lasts approximately 2 minutes. A blood sample will also be collected on the day of embryo transfer for biomarker analysis.
1. Patients who have signed the informed consent form 2. Patients with a body mass index (BMI) ≤30 kg/m² 3. Patients undergoing their first transfer cycle with a vitrified euploid blastocyst selected according to PGT-A 4. Patients eligible for a modified natural transfer cycle with ovulation trigger and luteal phase support 5. Patients with an endometrial thickness ≥ 7 mm and a trilaminar pattern on the day of the trigger visit 6. Patients scheduled for a single embryo transfer of a day 5 euploid blastocyst 7. Patients scheduled to undergo embryo transfer after 120 hours of progesterone exposure
1. Patients with a prior history of repeated pregnancy loss (two or more miscarriages). 2. Patients with a prior history of recurrent implantation failure (RIF), defined as failure of three or more transfers with A/B-quality embryos from at least two different cycles, or failure of one or more transfers with a euploid embryo. 3. Use of sperm obtained from a testicular biopsy. 4. Patients diagnosed with at least one of the following medical conditions: insulin-dependent diabetes mellitus, Cushing’s syndrome, uncorrected thyroid dysfunction, liver and/or kidney failure, or antiphospholipid syndrome. 5. Patients currently taking any anti-inflammatory drugs that may influence prostaglandin production (e.g., ibuprofen, naproxen, indomethacin, mesalazine). 6. Lack of adequate understanding, oral or written, of the clinical research protocol and informed consent form.